Scholarlink

Study Design <p>Retrospective, propensity score-matched cohort study.</p> Purpose <p>To determine if outcomes following spinal fusion differ between obese patients prescribed Tirzepatide and single receptor glucagon-like-peptide-1 (srGLP-1) agonists preoperatively.</p> Methods <p>Data was collected from the TriNetX Research Network. Obese patients undergoing spinal fusion that were prescribed tirzepatide alone in the 6 months preceding surgery, were matched 1:1 based on demographics, comorbidities, medication use, and surgical procedure with those prescribed an srGLP-1 agonist alone in the year prior to surgery. Early (90-day) outcomes included UTI, thrombotic or embolic events, and AKI. Long-term outcomes (2 years) include revision, pseudarthrosis, and post-laminectomy syndrome.</p> Results <p>A total of 918 matched pairs were analyzed. At 90-days after surgery, tirzepatide patients experienced fewer embolic or thrombotic events (RR 0.41, 95% CI 0.22–0.76, <i>p</i> = 0.003), lower UTI rates (RR 0.47, 95% CI 0.32–0.69, <i>p</i> &lt; 0.001) and less AKIs (RR 0.42, 95% CI 0.26–0.69, <i>p</i> &lt; 0.001) compared to srGLP-1 patients. At 2 years after surgery tirzepatide users had fewer instances of revision (RR 0.65, 95% CI 0.49–0.87, <i>p</i> = 0.003), pseudarthrosis (RR 0.41, 95% CI 0.25–0.68, <i>p</i> &lt; 0.001), post-laminectomy syndrome (RR 0.58, 95% CI 0.31–0.68, <i>p</i> &lt; 0.001) compared to srGLP-1 users.</p> Conclusions <p>In a propensity-matched analysis, obese spinal fusion patients treated with Tirzepatide compared to srGLP-1 agonists, had lower rates of early postoperative thrombotic and embolic events, UTIS, and AKIs. Additionally, the Tirzepatide fusion cohort had significantly lower rates of pseudarthrosis, revision surgery, and post-laminectomy syndrome 2 years after surgery. These findings support the potential protective physiological impact of Tirzepatide over srGLP-1s in obese patients undergoing spinal fusion.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Differential impact of pre-operative tirzepatide compared to glucagon-like-peptide-1 single receptor agonists on outcomes of spinal fusion surgery in obese patients

  • 期刊论文

  • 发表日期：

    2026年6月18日

查看全文
  • Gregory Isaac Sacks,
  • Yoli Meydan,
  • Ryan Lebens,
  • Harry M Mushlin

摘要

Study Design

Retrospective, propensity score-matched cohort study.

Purpose

To determine if outcomes following spinal fusion differ between obese patients prescribed Tirzepatide and single receptor glucagon-like-peptide-1 (srGLP-1) agonists preoperatively.

Methods

Data was collected from the TriNetX Research Network. Obese patients undergoing spinal fusion that were prescribed tirzepatide alone in the 6 months preceding surgery, were matched 1:1 based on demographics, comorbidities, medication use, and surgical procedure with those prescribed an srGLP-1 agonist alone in the year prior to surgery. Early (90-day) outcomes included UTI, thrombotic or embolic events, and AKI. Long-term outcomes (2 years) include revision, pseudarthrosis, and post-laminectomy syndrome.

Results

A total of 918 matched pairs were analyzed. At 90-days after surgery, tirzepatide patients experienced fewer embolic or thrombotic events (RR 0.41, 95% CI 0.22–0.76, p = 0.003), lower UTI rates (RR 0.47, 95% CI 0.32–0.69, p < 0.001) and less AKIs (RR 0.42, 95% CI 0.26–0.69, p < 0.001) compared to srGLP-1 patients. At 2 years after surgery tirzepatide users had fewer instances of revision (RR 0.65, 95% CI 0.49–0.87, p = 0.003), pseudarthrosis (RR 0.41, 95% CI 0.25–0.68, p < 0.001), post-laminectomy syndrome (RR 0.58, 95% CI 0.31–0.68, p < 0.001) compared to srGLP-1 users.

Conclusions

In a propensity-matched analysis, obese spinal fusion patients treated with Tirzepatide compared to srGLP-1 agonists, had lower rates of early postoperative thrombotic and embolic events, UTIS, and AKIs. Additionally, the Tirzepatide fusion cohort had significantly lower rates of pseudarthrosis, revision surgery, and post-laminectomy syndrome 2 years after surgery. These findings support the potential protective physiological impact of Tirzepatide over srGLP-1s in obese patients undergoing spinal fusion.